Point Biopharma CEO Joe McCann and Lantheus CEO Mary Anne Heino
November 14, 2022 09:57 AM EST
Deals

Aim­ing at main­stream mar­kets, ra­dio­phar­ma­ceu­ti­cal part­ners en­gi­neer $260M cash deal

Amber Tong

When Point Bio­phar­ma geared up to launch a Phase III tri­al for its PS­MA-tar­get­ing ra­di­oli­gand ther­a­py, one of the first things it did was to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times